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Abstract
Background: In developed countries, Clostridium difficile infection (CDI) represents an emerging threat in terms of
morbidity and mortality rates. In our country limited CDI epidemiological data can be found.
We have conducted a 6-year retrospective study to evaluate the incidence of CDI in Italian urban hospitals.
Methods: Stool samples tested for C. difficile toxins from January 2006 to December 2011 in 5 large hospitals in
Rome, Italy, were considered in the analysis. Repeated samples taken ≤ 2 months after a positive result were
excluded.
Results: A total of 402 CDI episodes were identified. The incidence of CDI episodes progressively increased from
0.3 in 2006 to 2.3 per 10,000 patient-days in 2011. CDI episodes mostly occurred in patients > 60 years of age (77%).
The >80 year-old age class reported the highest percentage of CDI episodes on tested samples (16%). Eighty
percent (80%) of CDI episodes occurred in medical wards followed by surgery (10.2%) and intensive care units
(9.8%).
Conclusions: A significant increasing incidence of CDI episodes over the study period was observed during the
years (p<.001), particularly in the older age groups. Medical wards experienced the highest number of CDI episodes
as compared to intensive care and surgical wards. The increasing rate of CDI episodes over the last six years in our
country, is alarming; urgent improvements in the surveillance systems and control programs are advisable.
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Background
Clostridium difficile infection (CDI) is the most frequent
cause of health care-associated infectious diarrhea in
industrialized countries. It predominantly affects elderly
and frail hospital and nursing home patients [1,2]. His-
torically, the attributable mortality of CDI has been
low, with death as a direct or indirect result of infection
occurring in less than 2% of cases [3], however, in re-
cent years, data from the literature show a marked
increase of C. difficile-associated mortality and case-
fatality rates [4-6].
Over the past decade, the incidence, prevalence and
associated mortality of CDI have increased, particularly
in North America and Europe [7-9]. In the United States
(US) the incidence of adult C. difficile-associated diarrhea
(CDAD) hospitalizations doubled from 5.5 cases per
10,000 population in 2000 to 11.2 in 2005, and the
CDAD-related age-adjusted case-fatality rate rose from
1.2% in 2000 to 2.2% in 2004 [4]. In Canada, Gravel et al.
reported a total attributable mortality rate of 5.7% among
patients with nosocomial CDI [2].
Similar concerns are documented in Europe. Asensio
et al. reported an increasing prevalence rate of CDI in
Spain from 3.9 to 12.2 cases per 10,000 hospitalised pa-
tients from 1999 through 2007 [10]; Burckhardt F et al.
reported that in Germany the incidence of CDI in-
creased from 1.7 to 14.8 cases per 100,000 people from
2002 to 2006 [11]. In the United Kingdom (UK) a six-
times increase in CDI related mortality from 1999 to
2006 was observed [6] and led to the introduction of
mandatory reporting of CDI cases for surveillance
purposes.
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In a study conducted in 14 European countries in
2005, Barbut et al. reported a mean CDI incidence of
2.45 cases per 10,000 patient-days [12]; whilst a more
recent European survey conducted in November 2008
collected data from 106 laboratories in 34 European
countries and reported a mean CDI incidence of 4.1 per
10,000 patient-days per hospital [13]. Both studies reported
the high variability in incidence of CDI among hospitals
and countries.
Epidemiological data from Italy regarding CDI rates
derive mainly from the European survey conducted in
2008, with only 5 Italian hospitals involved which in-
cluded 57 CDI cases on 533 tested patients [13]. A small
study in Bolzano, in the North of Italy, reported 13 cases
of nosocomial CDI from 163 tested patients [14].
The aim of this study is to assess the trend of CDI epi-
sodes in five urban Italian hospitals over a 6-year period.
Methods
A retrospective analysis of patients admitted to 5 urban
hospitals whose laboratories participated in a network,
in Rome, Italy from 2006 to 2011 was carried out. Rome
municipality has around 4 million inhabitants, and the
five hospitals in the study are large institutions account-
ing for a total of 2,677 beds (range 170–1,099), with an
average of 15,481 (range 3,312-40,343) admissions per
year.
All in-patients from whom stool samples were submit-
ted to the hospital laboratory for C. difficile toxin detec-
tion were considered in the analysis. A CDI episode was
considered as a positive C. difficile toxin assay in a stool
sample. Repeated samples taken within two months
after a positive result for any individual patient were ex-
cluded. Patients under 18 years of age were excluded
from the analysis.
In the stool samples the presence of toxin A and B was
tested through enzyme immunoassays for A/B toxins
(Table 1). Enzyme immunoassay for C difficile-specific
glutamate dehydrogenase and polymerase chain reaction
(PCR) were not routinely performed.
The data included patient demographics, ward and
specialty at the time of sample collection, date of sample
collection, type of test performed, and results.
Statistical analysis
CDI rates are expressed as the number of patients with
positive C. difficile toxin assay per 10,000 patient-days. A
linear trend test was performed over time using the
Cochran-Armitage test for trend. P values less than .05
were considered statistically significant. The analysis was
done with SAS, version 9.1 (SAS Institute).
The study involved the analysis of existing clinical and
laboratory data that were anonymised before being in-
cluded in the study database. Thus, according to local
and national regulations, this analysis was exempt from
review by the Ethics Committee.
Results
From January 2006 to December 2011, 4951 stool sam-
ples were tested for C. difficile toxins in five laboratories
of the hospitals participating in the study. A total of 402
CDI episodes were identified, accounting for 25, 33, 31,
43, 104, 166 in the years 2006, 2007, 2008, 2009, 2010,
2011 respectively. The incidence of CDI episodes per
10,000 patient-days significantly increased year by year,
reaching the highest rate in the year 2011, as shown in
Figure 1. This trend was attributable to increased num-
ber of episodes in elderly patients (Figure 2).
The overall incidence by hospital per 10,000 patient-
days ranged from 0.4 to 1.7 in the study period, as shown
in Table 1. However, in 2011, there was the highest rate of
CDI episodes per 10,000 patient-days, i.e. 4.0, in one of
the hospitals participating in the study.
The number of samples assayed increased from 511 in
2006 to 1485 in 2011. The proportion of these samples
identified as positive ranged from 4.9% in 2006 to 11.2%
in 2011 (Figure 3).
Regarding specialties, the highest proportion of CDI epi-
sodes on tested samples was found in surgery (11.1%),
followed by medicine (8.1%), and intensive care (6.4%).
However, in terms of raw numbers of cases, medicine far
outpaced others with a total of 322 CDI cases (80%)
(Figure 4). Regarding the distribution of positivity by ward,
80.1% occurred in medical wards, followed by surgery
(10.2%) and by intensive care units (9.7%).
The percentage of CDI episodes by stool samples in-
creased with age from 3.4% to 16.1% in 18–40 and > 80
age groups, respectively (Table 2).
Discussion
Our study provides a reliable estimate of the burden of
the disease in a large patient population (4951 patients),
Table 1 Number of samples tested (total and proportion
positive), and rate of Clostridium difficile infection (CDI)
episodes per 10,000 patient-days by hospital
Hospital CDI
episodes




1* 70 433 1.44
2‡ 69 411 1.01
3† 77 813 0.39
4* 138 1924 1.67
5† 48 1370 1.62
Overall 402 4951 0.87
* Meridian Immunocard (rapid EIA; Meridian Bioscence INC).
‡ Remel Xpect (rapid chromatographic immunoassay; Remel, Lenexa, KS, USA).
† TechLab Tox A/B Quik Chek (rapid antigen capture; TechLab).
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that underwent C. difficile toxin testing through a 6-year
period in 5 urban Italian hospitals. Data from our study
showed that the rate of CDI among patients undergoing
C. difficile toxin testing is on average 0.84 per 10,000
patient-days, and that this frequency significantly in-
creased during the years in the study, with the peak (i.e.
2.3 per 10,000 patient-days) in 2011.
Limited information on the burden of CDI in Italy is
available. Italian studies mainly focus on ribotyping of
collected strains or antimicrobial susceptibility testing
[15]. The rate of C. difficile infection in Italy is still un-
certain. Italian data on the incidence of CDI are derived
solely from a recent European survey and a single-
hospital study [13,14]. As such, the overall number of
patients tested is small (<1000).
Two European studies on nosocomial CDI conducted
in 2005 and 2008 reported an incidence of CDI of
2.45 per 10,000 patient-days and 4.1 per 10,000 patient-
days respectively [12,13]. However both reported a wide
range in incidence amongst different countries.
In the European hospital survey, 5 Italian hospitals
reported a mean CDI rate per hospital of 3.6 per 10,000
patient-days [13]. This represents a four-fold higher rate
compared with our average incidence rate over the
period examined, but only slightly higher if compared to
the 2011 rate alone (2.3 CDI episodes per 10,000 patient-
days). However, the Italian population analyzed in the
European survey is limited and is approximately one tenth
compared to our study. Furthermore in some Italian
hospitals participating in the survey, cytotoxicity test and
enzyme immunoassay for C. difficile-specific glutamate
dehydrogenase were also perfomed [13]. These test may
have a higher diagnostic sensitivity. In addition, unlike in
the European survey, where the CDI incidence was
Figure 2 Clostridium difficile infection (CDI) episodes by year and age group.
Figure 1 Distribution of Clostridium difficile infection (CDI) episode incidence per 10,000 patient-days from 2006 to 2011. Six hospitals
in Rome, Italy.
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evaluated in a one-month period, we evaluated CDI inci-
dence and trend over a 6-year period.
Interestingly, our trend is different from that described
in the US by Lucado et al. [16], that reported that in the
second half of the last decade the incidence rate appeared
blunted. Our rising trend appears to be more similar to
the first half of last decade in the Lucado study, thus hy-
pothesizing that a delay of CDI diffusion in our region
could have accounted for such a difference.
It is also of interest that in our study, there is a pro-
gressive increase in patients undergoing C. difficile toxin
testing in the 6-year period, and a parallel progressive
increase of CDI rates during the years. Increased testing
could be partly related to a higher antibiotic consump-
tion in the hospitals considered in the study, and partly
to a developing CDI awareness among healthcare profes-
sionals. In recent years there has been an increasing usage
of antimicrobials in the hospitals of Lazio Region, i.e. up
to 34% increase from 2007 to 2009 [17]. A similar increase
was found in Spain by Asensio et al., and was associated
with the increase of CDI prevalence rates [10].
Recently a new variable has been proposed for epi-
demiological studies on CD: C. difficile testing intensity
(CDTI). CDTI was defined as the total number of CD
test performed, normalized to the total number of pa-
tients with at least 1 CD test recorded. The authors ex-
plored this variable with the hypothesis that part of the
increase in CDI incidence is attributable to false posi-
tive related to repeated testing [18]. As a limitation of
our study, data on CDTI are not available in our study
population.
Our works demonstrate that the > 80 year-old age class
display the highest percentage of CDI episodes, and
overall the highest rates were reported in patients older
Figure 4 Clostridium difficile infection (CDI) proportion by stool samples assayed by ward.
Figure 3 Clostridium difficile infection (CDI) proportion by stool samples assayed by year.
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than 60 years. This finding reflects similar data from
previous studies conducted in the US [19] and Spain
[20], where significant increasing trends between 2000
and 2003 and 1997–2005, respectively, were reported in
both the older age groups with a larger increase in those
aged ≥ 65 than in those aged 45–64 [19,20].
Concerning the distribution of positivity by ward, in a
survey conducted in Canadian hospitals 53% of CDI oc-
curred in medical wards (including medicine unit, long-
term-care facility, oncology/hematology unit and transplant
unit), 23% occurred in surgical wards and 10% in intensive
care units [2], which is comparable to our findings.
Our study has some limitations. First, due to the retro-
spective design of the study, the clinical pictures of the
patients are not available. Secondly, data on C. difficile
testing intensity (CDTI) are not available in our study
population. CDTI has been proposed as a possible factor
associated with the incidence of hospital acquired CDI.
CDTI, defined as the total number of CD test performed,
normalized to the total number of patients with at least 1
CD test recorded, reflects the frequency of multiple test
recorded for a single patient, presumably in response to
an initially negative result [18]. This variable could limit
the possible bias deriving from repeat testing.
Another potential limitation could be an improved
sensitivity in laboratory procedures over time, leading to
an increased CDI detection. However, the participating
hospitals used the enzyme immunoassays for A/B toxins
for the study period, and no more sensitive/specific diag-
nostic tool (i.e. 2-step algorithm including glutamate de-
hydrogenase testing and molecular biology) was adopted
during the study period.
Data concerning antimicrobial consumption in the
surveyed hospitals during the study period are lacking.
We were unable to assess the rate of CDI episodes per
patient-days by ward, due to the unavailability of the
number of admissions per ward. Finally, data analised
according to subspecialty are not available either.
Conclusions
The increasing rate of CDI episodes in Italian hospitals
over the last six years represents a matter of concern for
our country; the emergence of hypervirulent C. difficile
strains, already circulating in Italy [21], is a cause of
further worry. An urgent need for improvements in the
surveillance systems and infection control programs, in-
cluding antimicrobial stewardship strategies, is advisable
in our hospitals.
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